IN-B001 CVA16 vaccine

IN-B001 CVA16 vaccine is an inactivated vaccine candidate designed to protect against disease caused by Coxsackievirus A16 (CVA16), one of the principal agents of hand, foot, and mouth disease (HFMD) in children. The vaccine is evaluated both as a monovalent (CVA16-only) and as part of a bivalent formulation with Enterovirus 71 (EV71), which together aim to address gaps in HFMD coverage not met by current vaccines. The vaccine works by generating an immune response against CVA16, specifically through the induction of neutralizing antibodies, and is currently in early clinical development for preventive use[1][3]. Developed by HK inno.N Corporation, the product addresses the absence of an approved CVA16 vaccine—a notable unmet need as current EV71 vaccines do not protect against CVA16-related HFMD[1][3].

Brand names

IN-B001IN-B-001IN-B 001

Other names

IN-B001 CVA16 vaccineIN-B-001 CVA16 vaccineIN-B 001 CVA16 vaccineIN-B001IN-B-001IN-B 001CVA16 inactivated vaccineCVA-16 inactivated vaccineCVA 16 inactivated vaccine